tbuckley/cabot-search huggingface dataset:
Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples
Authors: Beatriz Herreros, Shaomeng Wang, Maria E. Rodriguez, Margarita Sanchez-Beato, Elena Domenech, Raul Cordoba, Julio Delgado, Jose A Garcia-Marco, Juan F. Garcia, José Francisco Tomás, Joaquín Martínez-López, Jose Luis Bello, Antonia Rodriguez, Raquel Villuendas, Miguel A. Piris
Journal: Blood (2010)
Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)
Authors: Juan Gu, Francisco Hernandez-Ilizaliturri, Gregory P. Kaufman, Cory Mavis, Myron S. Czuczman
Journal: Blood (2012)
In-Hospital Mortality After Elective Abdominal Aortic Aneurysm Repair—Reply
Authors: Caitlin W. Hicks, Mahmoud B. Malas
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001.
Authors: Meir Wetzler, Wendy Stock, Kathleen A. Donohue, Kouros Owzar, Dorie A. Sher, Eva E. Hoke, John M. McCarty, William G. Blum, Bayard L. Powell, Clara D. Bloomfield, Charles A. Linker, Richard A. Larson
Journal: Blood (2007)
Imatinib Mesylate Impairs the Function of Human Regulatory T Cells (Tregs) and Reverses the Inhibition of Immune Responses to Imatinib-Resistant CML Cells by Tregs.
Authors: Masahiro Ogasawara, Toshihiro Matsukawa, Yuki Katsura, Kanako Shima, Minoru Kanaya, Mizuha Kosugi, Satomi Matsuoka, Shiro Fujii, Shinsuke Noguchi, Shuichi Ota, Masanobu Nakata, Kiyotoshi Imai, Teiichi Hirano, Naoki Kobayashi, Yoshio Kiyama, Masaharu Kasai
Journal: Blood (2009)
Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarbine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.
Authors: Gautam Borthakur, Stefan Faderl, Srdan Verstovsek, Dan Jones, Zeev Estrov, Susan O’Brien, Joyce Bass, Hagop Kantarjian
Journal: Blood (2008)
Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012
Authors: Lindsay M Morton, Graca M. Dores, Meredith S Shiels, Martha S Linet, Jop C Teepen, Clara J.K. Lam, Margaret A. Tucker, Rochelle E Curtis
Journal: Blood (2015)
M15 Evaluation of a novel intervention for patients with bronchiectasis: the bronchiectasis information and education feasibility (brief) study
Authors: KLM Hester, J Newton, T Rapley, A De Soyza
Journal: Thorax (2016)

<h3>Introduction</h3> There is currently limited information about bronchiectasis available to patients. We co-developed a novel patient and carer information resource, based on needs identified in previous work.<sup>1</sup> The resource was evaluated in the BRIEF study with the following objectives:- 1. To establish the feasibility of carrying out a multi-centre randomised controlled trial (RCT) to determine effect on understanding, self-management and health outcomes. 2. To evaluate and refine the intervention. <h3>Methods</h3> This was a feasibility study with a single-centre RCT design, comparing use of the resource to usual care in bronchiectasis.<sup>2</sup> Adults with bronchiectasis were recruited from respiratory clinics in the North of England. Those randomised to the intervention received the information resource (website www.bronchiectasis.me and booklet). Outcome measures (resource satisfaction, bronchiectasis knowledge, quality of life, unscheduled healthcare visits, exacerbation frequency, and lung function) were recorded at baseline, 2 weeks and 3 months. Feasibility outcomes included recruitment, retention and study form completion rates. A patient and carer focus group was held to discuss the intervention and the trial process. <h3>Results</h3> Recruitment rate was 50% of those assessed for eligibility (See Figure). Questionnaire completion rates were excellent with very few missing data. 24 participants were male and 38 female. Median age was 63 years (range 18–82). Participants reported using the information provided, and feedback was positive, particularly highlighting the usefulness of the video clips and self-management information. The most popular pages of the website included diet and lifestyle advice, advice for carers, and symptoms and prognosis. Focus group data reinforced users' positive experiences of the resource and the trial process. Full analysis is ongoing. <h3>Discussion and conclusions</h3> We have co-developed a multi-format, accessible information resource that could be made widely available outside of the specialist clinic setting. The BRIEF study suggests larger, definitive studies using interventions to improve understanding, compliance and self-management are warranted. Full results of the feasibility study are expected by December 2016. <h3>References</h3> Hester KLM, Newton J, De Soyza A, <i>et al</i>. Living your life with bronchiectasis: an exploration of patients and carers information needs informing development of a novel information resource. <i>Thorax</i> 2015;<b>70</b>(suppl. 3):A178. Hester KLM, Newton J, Rapley T, <i>et al</i>. Evaluation of a novel information resource for patients with bronchiectasis: study protocol for a randomised controlled trial. <i>Trials</i> 2016;<b>17</b>:210.
The association between drugs and bullous pemphigoid
Authors: C.W.X. Tan, Y. Pang, B. Sim, T. Thirumoorthy, S.M. Pang, H.Y. Lee
Journal: British Journal of Dermatology (2016)

Drug-induced bullous pemphigoid (DIBP) is often poorly defined in the existing literature from the classic, spontaneous form of bullous pemphigoid (BP). The pathogenesis is unclear and the association between bullous pemphigoid and various medications is tenuous1-2.Commonly reported associations include neuroleptics3-4and diuretics3, 5 with more recent literature drawing attention to dipeptidyl peptidase-4 inhibitors6.Strength of drug causality associations is generally determined by factors such as latency between drug initiation and onset of disease, epidemiological risk, effects of withdrawal/re-challenge. Prior drug association studies were based on broader inclusion criteria and may overestimate the true association3-6.

This article is protected by copyright. All rights reserved.
Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.
Authors: Tadeusz Robak, Rick Aultman, Stephan H.K. Oertel, Emma SC Carr
Journal: Blood (2009)
High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia
Authors: David Wu, Anna Sherwood, Stuart S. Winter, Kimberly Dunsmore, Mignon L Loh, Jonathan R Fromm, Harvey A Greisman, Daniel E. Sabath, Brent L. Wood, Harlan Robins
Journal: Blood (2011)
Immunologic Recovery after Nonmyeloablative (NM) Conditioning: A Comparison between Related Versus Unrelated Donor Hematopoietic Cell Transplantation (HCT).
Authors: Frederic Baron, M. Maris, J. Storek, M. Metcalf, K. White, B. Sandmaier, D. Maloney, R. Storb, M. Boeckh
Journal: Blood (2005)
Immature Platelet Fraction in Different Diagnosis of Thrombocytopenic States: An Approach to Distinguish Idiopathic Thrombocytopenic Purpura from Myelodysplastic Syndrome with Isolated Thrombocytopenia.
Authors: Koji Miyazaki, Miyako Taira, Tomiteru Togano, Manabu Ohsaka, Yuhko Suzuki, Mikio Danbara, Ryouichi Horie, Masaaki Higashihara
Journal: Blood (2006)
AB0572 Impact of Aging on The Clinical Features and Treatment of Anca Associated Vasculitis in The Elderly
Authors: S. Sato, T. Asano, H. Kobayashi, H. Watanabe, H. Ohira
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ANCA associated vasculitis (AAV) usually occurs in elderly patients, but only a few studies regarding clinical features and treatment of elderly onset AAV have been reported so far<sup>1,2)</sup>. <h3>Objectives</h3> To compare clinical features and treatment of AAV between elderly patients (≥75) and younger patients (&lt;75) in Japanese patients. <h3>Methods</h3> Patients who met the criteria for granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS) were included in this study. AAV patients (N=31) who were initially treated at Fukushima Medical University Hospital (Fukushima, Japan) from 2004 to 2015 were retrospectively reviewed. These patients were divided into 2 groups (elderly, N=9 and younger, N=22) and compared for the following clinical features, laboratory data and treatment: age at diagnosis, sex, Birmingham Vasculitis Activity Score (BVAS), symptoms, liver and renal function, hemoglobin, serum ferritin levels, IgG, ANCA (MPO/PR3) positivity, and therapy (prednisolone and immunosuppressive therapy). <h3>Results</h3> Following 31 AAV patients were identified: 8 cases of GPA, 20 cases of MPA, and 3 cases of CSS. Elderly group showed significantly lower frequency of skin manifestation and significantly higher frequency of kidney symptoms. In laboratory data, elderly group showed significantly lower serum AST, LDH and Ferritin levels. As to therapy, elderly patients received significantly lower prednisolone doses and frequency of cyclophosphamide (CYP) administration. Mortality rates (1 year) were significantly higher in elderly group (33.3%) than younger group (4.6%). Four patients died: all patients were MPA and the main causes of death were vasculitis progression (alveolar hemorrhage) and infection. <h3>Conclusions</h3> This study shows that the clinical features of elderly AAV patients are comparable to those of younger patients in Japan, except for lower skin manifestations and higher kidney symptoms. Lower AST, LDH, and ferritin levels in elderly AAV may indicate that elderly patients show milder organ damage on admission. Higher mortality rates in elderly AAV may be associated with lower PSL doses and frequency of CYP administration. Proper immunosuppressive therapy should be considered to reduce mortality rates for vasculitis progression or severe infection in elderly AAV. <h3>References</h3> Hoganson et al. J Clin Rheumatol. 2008. Weiner et al. Clin J Am Soc Nephrol. 2015. <h3>Disclosure of Interest</h3> None declared
Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.
Authors: Wanlong Ma, Iman Jilani, Benjamin Bekele, Hagop Kantarjian, Amber Donahue, Xi Zhang, Zhong Zhang, Susan O’Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Blood (2007)
Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies
Authors: Norma C. Gutierrez, Roberto JP Magalhaes, Ramón García-Sanz, María-Belén Vidriales, Enrique M. Ocio, Bruno Paiva, Daniel del Carpio, Alvaro Caballero, Jennifer Alonso, Lucia Lopez-Anglada, Teresa Villaescusa, Jesus M. Hernandez Rivas, A. Aguilar, Alejandro Martín, R. Lopez, Alberto Orfao, Jesus F San Miguel
Journal: Blood (2010)
Long-Term Outcome of Iron-Induced Cardiac Disease in Patients with Thalassemia Major Treated with Combined DFP/DFO or DFO Alone.
Authors: Maria Eliana Lai, Stefania Vacquer, Alessia Pepe, Aurelio Maggio, Maria P. Carta, Paolo Cianciulli, Patrizio Bina, Franco Sau, Robert W. Grady
Journal: Blood (2006)
SP0092 Digital Interventions To Improve Self-Care for Long Term Conditions
Authors: E. Murray
Journal: Annals of the Rheumatic Diseases (2016)

People living with a long term condition (LTC), such as diabetes or rheumatoid arthritis have to learn to live with their health problem and to manage the consequences. Not managing is not an option – what varies is the degree to which self-management improves or harms overall health and wellbeing. Corbin and Strauss have defined three tasks for patients with an LTC: medical management; emotional management; and role management. Medical management includes adopting healthy behaviours such as healthy eating, physical activity, working with health care professionals and taking medication as prescribed. Less well recognised, but equally challenging, are managing the emotional reactions of having a long term condition, including anger, despair, shame and guilt; and the changes to one9s role, or biographical narrative. For many people a diagnosis of a serious illness fundamentally alters their perceptions of their essential self, and their role in life. Digital health interventions (DHI) have significant potential for helping people undertake these three tasks. DHI are interventions which are delivered digitally, e.g. over the web to a PC, tablet or phone, or via an app. They can combine information with interactive components such as decision support, emotional support and behaviour change support, and often deliver treatments that have previously been offered face to face, such as cognitive behavioural therapy, mindfulness training, or medication changes according to pre-defined algorithms responding to self-monitoring data entered by patients. The use of video, audio and graphics can make complex information accessible and comprehensible to people with low literacy, or poor language skills. Software programming allows information and responses to be tailored to each individual, reflecting specific needs. In this talk I will explain how DHI can help patients with the complex tasks of self-management, providing examples of available interventions. I will also summarise the research evidence on their uptake, acceptability and effectiveness. <h3>Disclosure of Interest</h3> None declared
Discovering Regulatory SNPs by Genome-Wide Analysis of Differential Scl/TAL-1 Occupancy in Human Primary Erythroid Cells,
Authors: Marco De Gobbi, Jim R. Hughes, Karen M. Lower, Chris J. Derry, Emanuele Marchi, Jacqueline Sloane-Stanley, Nigel Roberts, Stephen Taylor, Catherine Porcher, Richard J. Gibbons, Douglas R. Higgs
Journal: Blood (2011)
LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
Authors: J. Bennouna, P.-L. Etienne, E. Bogart, M.-P. Galais, M. Benabdelghani, E. Francois, P. Michel, L. Dahan, J.-P. Metges, F. Ghiringhelli, T. Conroy, N. Kotecki, L. Bedenne, F. El Hajbi, E. Samalin, G. Piessen, S. Delaine-Clisant, N. Penel, C. Mariette, A. Adenis
Journal: Annals of Oncology (2016)
Preserving Physical Diagnosis—A Time-honored Art
Authors: Susan Burgin, Jeffrey M. Cohen
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P293 Drug delivery performance of budesonide (BD), glycopyrronium (GP) and formoterol (FF) triple combination (BGF) co-suspension™ delivery technology mdis
Authors: V Joshi, P Mack, J Archbell, G Li, M Arent, K Vang, S Ivatury, R Schultz, D Lechuga-Ballesteros, S Dwivedi, M Riebe
Journal: Thorax (2016)

<h3>Introduction</h3> To assure consistency of clinical outcomes, orally inhaled products must have consistent <i>in vitro</i> delivered dose and aerosol properties. Achieving this consistency has been challenging with MDIs, particularly those that combine multiple drugs. Co-Suspension™ delivery technology has been developed for <i>in vitro</i> drug-drug interaction-free delivery of multiple drugs from fixed-dose MDI combinations. This versatile technology suspends the micronised drugs with spray-dried phospholipid porous particles in hydrofluoroalkane propellant. The objective of this study was to determine whether BGF MDI, the triple Co-Suspension delivery technology formulation of BD/GP/FF, displays <i>in vitro</i> drug delivery comparable to its constituent single and dual drug formulations. <h3>Methods</h3> Single, dual and triple therapy MDIs of BD, GP and FF were prepared by suspending each drug’s microcrystals with phospholipid porous particles in HFA propellant. <i>In vitro</i> drug delivery was assessed by comparing delivered dose uniformity and aerodynamic particle size distribution. <h3>Results</h3> BD, GP and FF formed stable suspensions in the presence of phospholipid porous particles, despite differences in drug physicochemical properties and doses. A consistent and comparable delivered dose and aerodynamic particle size distribution was observed whether emitted from a single, dual or triple therapy MDI. <h3>Conclusion</h3> The single, dual and triple drug MDI formulations demonstrated comparable aerosol characteristics which should enable patients to transition across the continuum of these MDI therapies without <i>in vitro</i> drug-drug interaction impacting drug delivery and clinical outcomes.
PTH-098 Audit of Current Liver Biopsy Practice at A Single Tertiary Centre
Authors: R Harrison, I Patanwala
Journal: Gut (2016)

<h3>Introduction</h3> In an era of increasing availability and access to well validated non-invasive laboratory diagnostic screens and measures of liver fibrosis, the role of liver biopsy for diagnosis and staging of liver disease has diminished. Liver biopsies are subject to sampling error which is made worse by inadequate sample sizes. There is no data on the adequacy of liver biopsy specimens when obtained percutaneously as opposed to the transjugular route.We aimed to assess the adequacy of liver biopsy samples as defined by the minimum standards suggested by the Royal College of Pathologists’(RCP),<sup>1</sup> UK (minimum of 6 portal tracts and sample length of 15 mm). Where available we wished to compare the results of biopsy fibrosis staging with transient elastography data. <h3>Methods</h3> A retrospective study was designed to review all liver biopsy requests made in our tertiary liver unit between 31 st October 2012 and 24 June 2013. <h3>Results</h3> 114 patients(59.6% male) with a median age of 48.7(interquartile range 19.8) had a liver biopsy. The commonest indications for biopsy were deranged liver function tests and queries regarding aetiology. Out of 114 reports 82 (71.9%) included the number of portal tracts and length of the biopsy and of these 52 (63.4%) were adequate samples as per RCP standards.<sup>1</sup>The number of transjugular liver biopsy reports were 16 (14.0%) and of these only 5 (31.3%) mentioned the size and number of portal tracts. Of these only 1 (20%) sample was adequate as per RCP standards.<sup>1</sup> Of the 98 (86.0%) percutaneous samples 77 (78.6%) reported the length and number of portal tracts and only 51 (66.2%) were adequate. Of the 114 patients, 54 (47.3%) had transient elastography within 12 months of the liver biopsy with 47 (87.0%) having a score above 7 kPa suggestive of abnormal liver stiffness. The 26 (48.1%) with a score above 12.2 kPa which is indicative of cirrhosis only 9 (34.6%) had a histological diagnosis of cirrhosis. Of the 13 (24.1%) patients who had a normal liver stiffness picture on transient elastography with a score below 7 kPa none had a histological diagnosis of cirrhosis. <h3>Conclusion</h3> Assessment of sample adequacy was compromised because only two-thirds of the reports contained the recommended information to confirm adequacy. Of those where this information was present 36.6% of samples did not meet minimum standards set by the RCP<sup>1</sup> which may impact on histopathological diagnosis. The audit showed that patients with a low transient elastography were unlikely to have a histological diagnosis of cirrhosis. Patients with a raised transient elastography only a third were identified as being cirrhotic on biopsy suggesting further clinical correlation is required. <h3>Reference</h3> 1 Wyatt J, <i>et al</i>. Tissue pathways for liver biopsies for the investigation of medical disease and for focal lesions Royal College of Pathologists’ Guidelines. 2014. <h3>Disclosure of Interest</h3> None Declared
SP0167 Outcome Assessment in SLE
Authors: R. Fischer-Betz
Journal: Annals of the Rheumatic Diseases (2016)

Outcome is defined as "something that follows as a result or consequence of an activity or process". Although the outcome of patients with SLE has improved within the last decades (e.g. considering mortality rates), the disease is a condition still associated with considerable burden and increased morbidity. In routine care the assessment of SLE patients is biased by the experience of the treating physician which leads to significant variability. This may impact quality of care offered to patients and ultimately influence outcomes. Almost five years ago, a 9core set9 of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed which includes e.g. disease activity, damage and co-morbidities. More recently, targets have been defined in order to improve the long-term outcome. In this context, consensus definitions of "low disease activity state" (LLDAS) and of "remission" in SLE were generated. First retrospective studies showed that e.g. achievement of LLDAS was associated with significantly reduced organ damage accrual. Therefore in 5 years from now, outcome assessment will hopefully change from a "passive approach" to an active process leading to targeted treatment decisions. <h3>Disclosure of Interest</h3> None declared